Changes in regulation surrounding marijuana have sprouted a robust medical cannabis market showing no signs of slowing down globally. Currently, the U.S. dominates the cannabis market where the majority of States started adopting the new trend for cannabis treatment in 2012. Australia has been late to the game; we only began easing laws in early
Read More
Cannabis is having a major moment these past few years, trending in research and trickling down into the retail sector. Medicinal cannabis company Bod Australia (ASX: BOD) has been selling cannabidiol (CBD) food products within the UK for a while now, however recent legislative changes around the substance dictate that manufacturers now require approval to
Read More
With rising COVID cases around the world following the latest Omicron strain outbreak, UK regulators are willing to try anything to reduce the mortality rate of COVID-19, including the use of medicinal cannabis for which Bod Australia (ASX: BOD) has been approved to commence clinical trials. The Clinical Trial Authorisation (CTA) has been granted by
Read More
In a key advancement within Australia’s emerging medicinal cannabis market, Bod Australia (ASX: BDA) has commenced a national study which will be conducted over 12 months to trial the effectiveness of MediCabilis™ as a treatment for anxiety, insomnia and Post Traumatic Stress Disorder (PTSD). The study will be conducted Australia-wide with Bod having partnered with
Read More
Cannabis healthcare company Bod Australia (ASX: BDA) has commenced its penetration of the lucrative UK medicinal cannabis market having received its first international prescriptions for their MediCabilis™ product. With more than 7.3 million consumers of cannabis products in the UK annually, it represents a major addressable market for Bod which estimates its value to be
Read More